Abstracts tagged "risk factors"

Abstract Number: 0847 • ACR Convergence 2025
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
Stefano Di Donato¹, Rebecca Ross², Marco Minerba³, Vishal Kakkar⁴, Enrico De Lorenzis⁵, Philip Yee⁶, Christopher Denton⁷ and Francesco Del Galdo⁴, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁶UCL, London, United Kingdom, ⁷University College London, UK, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by vascular damage, immune dysregulation, and fibrosis. It is typically classified into limited cutaneous (lcSSc)…
Abstract Number: 0161 • ACR Convergence 2025
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Madiha Naqsh Siddiqui¹, Yen Chen¹, Rosemary Gedert², Suiyuan Huang², Dinesh Khanna² and John Varga², ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
Abstract Number: 2383 • ACR Convergence 2025
The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Cristina Reategui-Sokolova⁴, Claudia Elera-Fitzcarrald⁴, Cesar Pastor-Asurza⁵, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: The CCI has been associated with adverse health-related outcomes in SLE-patients worldwide. Its modified version, the age-adjusted CCI (ACCI) has been associated with organ…
Abstract Number: 1716 • ACR Convergence 2025
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Jessica Fairley¹, Laura Ross¹, Elizabeth Paratz², Penelope McKelvie³, Simin Daneshvar³, Shereen Oon⁴, Dylan Hansen³, Wendy Stevens¹, Andre La Gerche² and Mandana Nikpour⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ⁵University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: Cardiovascular disease is the leading cause of death in systemic lupus erythematosus (SLE).1 Whilst histopathology remains the gold standard for establishing the pathogenesis of…
Abstract Number: 1148 • ACR Convergence 2025
Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center
Alana Haussmann¹ and Elizabeth Volkmann², ¹University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and clinical features of at least…
Abstract Number: 0833 • ACR Convergence 2025
Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA
Timothy Wilson¹, Claudia Lugo², Marie Feser³, Mark Gillespie⁴, Troy Torgerson⁵, Gary Firestein⁶, V. Michael Holers⁷, Kevin Deane⁸ and Kristen Demoruelle⁹, ¹Thomas Jefferson University, Philadelphia, PA, ²University of Colorado, Denver, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Allen Institute for Immunology, Enumclaw, WA, ⁶University of California, San Diego, San Diego, CA, ⁷University of Colorado Anschutz Medical Campus, Aurora, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: The presence of serum anti-CCP-IgG antibodies can predict the future development of clinically evident RA. Neutrophil extracellular trap (NET) formation can be a source…
Abstract Number: 0148 • ACR Convergence 2025
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Coralie Cruzel¹, antonio Iannelli², Alexandre Armengaud³, Sonia Oppo³, Marie Charlotte Trojani⁴, Stephanie Ferrero⁴, Veronique Breuil⁴, Eric Fontas⁵, Christian Roux⁴ and Clément Viala⁴, ¹². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, ²³. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet ² Hospital, ⁰⁶²⁰² Nice, France., NIce, France, ³¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, ⁴¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, ⁵². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 1700 • ACR Convergence 2025
Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions
Mikhail Olferiev¹, Kyriakos Kirou¹, Emily Wu², Dina Greenman¹ and Mary Crow³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Union City, NJ, ³Hospital for Special Surgery, New York
Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the…
Abstract Number: 1137 • ACR Convergence 2025
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Miriam Paz³, Chanokporn Puchongmart¹, Ben thiravetyan¹, Panat Yanpiset¹ and Jerapas Thongpiya⁴, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…
Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Hana Hulejová¹, Nora Růžičková², Petra Hánová¹, Jiri Vencovsky³, Ladislav Šenolt², Jiří Štolfa² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Mitndbaim Parra¹, Marta Flores², María Ángeles Puche-Larrubia³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
Abstract Number: 1681 • ACR Convergence 2025
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Belén Serrano-Benavente⁷, Judit Font-Urgelles⁸, Angel Garcia-Aparicio⁹, Sara Manrique-Arija¹⁰, Jesús Alberto Garcia Vadillo¹¹, Ruth Lopez-Gonzalez¹², Javier Narváez¹³, Maria Beatriz Rodriguez¹⁴, Carlos Galisteo¹⁵, Jorge Juan Gonzalez Martin¹⁶, Paloma Vela Casasempere¹⁷, Rabadán Elena¹⁸, Antonio Naranjo¹⁹, Beatriz Paredes-Romero²⁰, Leyre Riancho-Zarrabeitia²¹, Sheila Melchor Diaz²², Irene Altabás-González²³, Sergi Heredia Martin²⁴, Clara Moriano²⁵, Mª Angeles Blazquez Cañamero²⁶, Paula Estrada-Alarcón²⁷, Enrique Judez²⁸, Nerea Alcorta Lorenzo²⁹, Javier Loricera³⁰, Rosalía Martínez Pérez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Hospital Regional Universitario Málaga, Malaga, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Zamora Health Complex, Salamanca, Spain, ¹³Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁵Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁶HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ¹⁹Hospital Dr Negrin, PALMAS DE GRAN CANARIA (LAS), Spain, ²⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²¹Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²²¹² de Octubre University Hospital, Madrid, Spain, ²³Complejo Hospitalario de Vigo, Vigo, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶Hospital Ramon y Cajal, Madrid, Spain, ²⁷Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁸Albacete University Hospital, Albacete, Spain, ²⁹University Hospital Donostia, san sebastian, Spain, ³⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…

« Previous Page
1
…
3
4
5
6
7
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].